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Gene therapys become a promising therapeutic avenue for a variety of incurable diseases. This
technology is an intracellular application of gene-engineered antibodies, aimed at ablating the abnormal
function of intracellular molecules. Parkinson's disease (PD) is a common neurodegenerative disease with no
cure. Recent studies have explored possible intrabody applications against alpha-synuclein (α-syn), whose
misfolding is believed to cause a familial form of PD. Here, we review the origin, production, and therapeutic
mechanisms of intrabodies and the potential of intrabody protection against α-syn toxicity. Furthermore, we
propose possible intrabody applications against leucine-rich repeat kinase 2 (LRRK2), whose mutations are
the most frequent known cause of familial and sporadic PD.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Recently, the intrabody technology has emerged as a novel tool
to modulate the function of intracellular proteins [1]. Moreover, this
technology has been applied in various research settings that model
complex human pathological conditions such as Parkinson's disease
(PD), the second most common neurodegenerative disorder after
Alzheimer's dementia [2]. The pathological features of PD include a
loss of dopaminergic neurons in the substantia nigra pars compacta
[3] and the formation of the Lewy body (LB), a cytoplasmic
proteinaceous inclusion composed principally of alpha-synuclein
(α-syn) [4]. Currently, while medicines such as Levodopa may help
tomanage symptoms, to date, no treatment has been shown to slowor
stop the progression of PD. Although PD arises essentially as a sporadic
condition, it is occasionally inherited [5]. In the past decade, studies on
various proteins, such as α-syn, parkin, DJ-1, PTEN-induced putative
kinase 1 (PINK1), and leucine-rich repeat kinase 2 (LRRK2), whose
genetic mutations cause familial PD, have largely improved our
understanding of possible pathogenic mechanisms of PD and have
provided us with potential therapeutic targets for PD.
Based on a paucity of available intrabody studies in PD, the
intrabody therapy for this common disorder has unambiguously a
long path to explore. However, it holds one of the promises of a cureolumbia University, 650 West
).
ll rights reserved.for PD since it aims to remedy the pathogenic abnormalities at the
molecular level. In this review, to provide a general background, we
will ﬁrst discuss the origin, production and therapeutic mechanisms
of intrabody. Then, we will discuss intrabody studies in PD, with focus
on α-syn. Finally, we will propose potential intrabody applications to
prevent the cellular toxicities caused bymutant LRRK2, shedding light
on intrabody studies in new PD-related scenario.
2. Antibody and scFv
Antibodies, or immunoglobulins, are one of the major protein
effectors of an immune system. A typical antibody molecule consists
of two heavy chains and two light chains, connected by disulﬁde
bonds. Compared to the constant regions (CH and CL), which share
high homology among different antibodies, the variable regions (VH
and VL) are extremely variable, forming a unique three-dimensional
structure, the antigen-binding site or Fv (Fig. 1). The Fv binds a
structurally complementary molecule, known as an antigen (Ag). The
high variability of Fv makes it possible for a natural antibody pool to
recognize a broad range of antigens.
Antibodies have been broadly used for disease diagnosis and
therapy mainly due to their high speciﬁcity and high afﬁnity. An
antigen determinant, also termed epitope, is the portion of an antigen
that binds to an antibody. Antibody speciﬁcity is the property that
enables antibodies to discriminate between two different antigen
determinants. The strength with which an antibody binds to an
antigen determinant is called afﬁnity, usually described by the
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described the monoclonal antibody (MAb) technology in 1975 [6], an
ideal MAb with both high speciﬁcity and high afﬁnity has been
believed to be a “magic bullet” for target therapy. Although initial
clinical trialswithMAbs showed somepromising antitumor effects [7],
MAb therapy is hindered by the following major obstacles: human
antimouse antibody (HAMA) responses generated by the immuno-
genicity of mouseMAbs, difﬁculties in identifying speciﬁc targets such
as tumor-speciﬁc antigens, and the low efﬁcacy of antibody enrich-
ment at affected tissues [8].
To overcome the above issues, in vitro antibody display technol-
ogies have been developed to display a large repertoire of gene-
engineered antibodies (N109 members) on the surfaces of phage,
yeast, or others, for rapid screening of a speciﬁc antibody of interest
[9–14]. Gene-engineered antibodies refer to recombinant antibody
molecules that are generated by expressing the cDNA of engineered
antibody fragments, such as “VH-linker-VL” (Fig. 1). Usually, the
engineered antibody fragments contain at least one complete or
partial antigen-binding site to retain antigen-binding function. Gene-
engineered antibodies consist of many types of antibody molecules,
such as single-chain Fv (scFv, ∼25 kDa) and Fabs (antigen-binding
fragments, ∼55 kDa) (Fig. 1). Here, throughout this review, for the
simplicity of demonstration, we use scFv to represent all other gene-
engineered antibodies.
ScFv, a keymolecule of gene-engineered antibodies, is composed of
the VH and VL regions, which are connected by a ﬂexible short linker
with a major form of (Gly4Ser)3 (Fig. 1) [15]. ScFv is attractive due to
the following advantages. First, it has a small size of ∼25 kDa (vs
∼150 kDa of a typical antibody), yielding rapid renal elimination and
better tumor tissue penetration [16–18]. Yet, it retains good antigen-
binding speciﬁcity because the antigen-binding site is unaltered.
Second, to generate an scFv, the coding gene segments of VH and VL
regions are isolated either from a hybridoma expressing the MAbwith
desired speciﬁcity [19], or from a large antibody librarywithmore than
109 members of diverse scFvs; the latter gives the potential for
screening scFvs against virtually any possible antigen in a short time
[20]. Third, most antibody libraries contain scFvs as human proteins,
which do not induce HAMA responses, because these scFvs are made
from the coding genes of VH and VL regions from human lymphocytes.
Fourth, optimized scFv functional characteristics, such as high afﬁnity,Fig. 1. Schematic representation of antibody, scFv, and intrabody molecules. A typical antibo
bond linked domains. Each chain has a variable region (VH or VL) and a constant region (CH
regions, a Fab molecule contains a light chain (VL and CL), a VH region and the ﬁrst domain o
form scFv, a single valent antigen-binding molecule. In the cytosol of mammalian cells, ba
functional antigen-binding molecules.long retention time (the capability to stay in antigen-binding status),
and enhanced protein stability, can be achieved by further mutagen-
esis of the scFv cDNAs and by further selection from sub-libraries
containing these mutated scFvs [21]. Clearly, scFvs and other gene-
engineered antibodies represent a type of promising reagent for
targeted therapy. Furthermore, innovative technologies have largely
improved the likelihood of an antibody being a “magic bullet” and are
still undergoing further development, especially in the improvement
of minimizing immunogenicity, in increasing speciﬁcity, afﬁnity, and
stability, and in employing new application scenarios. For example,
recently, the application of scFv inside of human cells has become a
completely novel type of molecular therapy, intrabody therapy.
3. Intrabody
Intrabodies, or intracellular antibodies, here refer to gene-
engineered antibodies (mainly scFvs) that are expressed intracellu-
larly to modulate the function of their intracellular targets. Usually,
cell transfections or infections with scFv cDNA-containing plasmids or
viruses are the means to express scFvs intracellularly. Clearly, the
intrabody technology is an intracellular application of gene-engi-
neered antibodies.
3.1. Challenges
To use scFvs intracellularly, a major obstacle is the fact that the
cytoplasmic reducing environment prevents the formation of disulﬁde
bonds. As shown in Fig. 1, disulﬁde bonds are necessary for optimized
folding of the antigen-binding site of scFv [22]. Thus, for most scFvs
isolated from antibody libraries or from hybridomas, the antigen-
binding capacities are more or less decreased or even completely lost
when these scFvs are expressed as intrabodies in the cytosol (Fig. 1)
[23,24]. For this reason, to select the scFvs that can bind their antigens
inside cells, researchers have developed the following two strategies:
a) in vitro screening of scFvs from antibody libraries followed by
further intracellular validation in mammalian cells [25,26]; b)
intracellular scFv screening to identify intracellular functional scFvs
directly [27–29]. As a result, the most critical parameter of a successful
intrabody is its intrinsic folding capacity under a reducing environ-
ment, rather than its in vitro afﬁnity [30]. In addition, there are otherdy structure consists of two heavy chains and two light chains, which contain disulﬁde
or CL). While the antigen-binding site, Fv, refers to the structure formed by VH and VL
f a CH region, linked by disulﬁde bond. The VH and VL, linked by a ﬂexible linker peptide,
sed on its intrinsic folding property, scFvs have various stabilities in terms of forming
Fig. 2. Schematic representation of the production of scFvs of interest, identiﬁcation of
functional intrabodies, and further optimization of intracellular stability and afﬁnity.
This approach applies with various antibody display systems, including phage display
and yeast display antibody technologies, toward yielding robust intrabodies as
therapeutics.
Fig. 3. A central molecular hypothesis for the intrabody therapy against the α-syn
pathology. By blocking α-syn self-aggregation, intrabodies restore the balance between
thenatively unfolded structure ofα-synand its orderedphysiological structures, rendering
therapeutic effects.
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gene delivery, which are not in the scope of this review.
3.2. Production of intrabodies
As mentioned above, intrabodies can be generated by using direct
intracellular scFv screening methods [27–29]. However, while these
methods are waiting to be widely applied and tested, the following
strategy remains as a feasible and widely used method to generate
functional intrabodies (Fig. 2).
First, antigens are usually produced as recombinant proteins by
expressing the antigen cDNAs in bacteria, followed by protein
puriﬁcation. Of note, some eukaryotic proteins require post-transla-
tional modiﬁcations for maximal folding/activity, whereas bacteria do
not have the machinery required to accomplish complex modiﬁca-
tions. Therefore, when these modiﬁcations are necessary, eukaryotic
cells, such as yeast cells and insect cells, can be used for the production
of recombinant proteins. In the cases that recombinant proteins are
not readily available, or scFvs against speciﬁc epitopes are needed,
synthesized peptides are often used as antigens. Numerous antibody
libraries are available for scientiﬁc studies, such as synthetic phage
libraries (the Tomlinson I and J antibody libraries, MRC Center for
Protein Engineering, Cambridge, England) and naïve yeast libraries
[11]. With the antigen and antibody libraries available, one can screen
a set of scFvs speciﬁcally against an antigen according to standard
protocols [9,11]. Once a set of binders are selected, it is important to
characterize their in vitro features, including speciﬁcity, afﬁnity, and
epitopes. From this in vitro characterization, a set of scFvs with good
antibody features usually can be acquired. However, only the scFvs
with functionally intracellular binding to their speciﬁc targets can be
used as intrabodies (see later discussion in the section of In vitro
versus in situ characterization of scFvs).
3.3. Therapeutic strategies
Since 1988, when a study showed that intracellular expression of
the cDNAs of antibody heavy and light chains against yeast alcohol
dehydrogenase I successfully inactivated the enzyme in vivo [31], the
intrabody technology has been broadly employed in the studies
involving human diseases, mainly AIDS and cancer. The following
strategies are used for intrabodies to ablate or restore the function of
intracellular molecules. First, intrabodies can block the interaction
between their target proteins and other molecules, such as proteinsand nucleic acids. For example, human immunodeﬁciency virus type
1 (HIV-1), protein Tat functions through binding with human cyclin
T1 to promote the transcription elongation of HIV-1. By disrupting
the molecular interaction between HIV-1 Tat and human cyclin T1,
anti-human cyclin T1 intrabodies effectively block HIV-1 replication
without causing cellular toxicity [32]. Second, by retaining their
targets in a particular subcellular compartment, such as endoplasmic
reticulum (ER), intrabodies can prevent their target molecules from
being at their physiological locations to function [33]. In fact, by
attaching an organelle-targeting sequence to an intrabody, the
expression of intrabodies at speciﬁc subcellular compartments can
be achieved, such as in nuclei, ER and lysosomes [34]. For instance,
tagged with the ER-retention signal (SEKDEL), an anti-gp120
intrabody has been used to trap gp120, an envelope protein of
HIV-1, inside the lumen of ER to prevent the assembly of new
infectious virions [35]. Third, intrabodies can restore normal protein
function that has been lost due to mutagenesis. For instance, p53 is a
tumor suppressor gene that is mutated in ∼50% of cancers. Mutation
of p53 results in a loss of function of p53 protein by diminishing its
DNA binding activity, which is required for its tumor suppressor
function. An anti-p53 intrabody has been shown to restore the
normal conformation and DNA binding activity of p53 and thus to
suppress tumor progression [36]. Fourth, intrabody can prevent
aberrant protein conformation and protein aggregation. This aspect
will be discussed later in the section called α-Syn.
3.4. Advantages
Obviously, intrabodies are valuable for both functional studies of a
given intracellular molecule and the development of novel therapeu-
tics. In fact, compared to other similar technologies aimed at blocking
protein function, such as RNA interference (RNAi), the intrabody
technology has the advantage of modifying certain domains of a
protein without affecting other domains because intrabodies have
domain-speciﬁc binding capabilities. In addition, intrabodies can also
modify the three-dimensional structure of a protein and thus are
important for both stabilizing active protein conformations and
correcting aberrant protein conformations. The abnormal protein
conformations are closely related to the pathogenic mechanisms of
neurodegenerative diseases, such as PD. Moreover, for proteins with
relatively long half-lives or for proteins whosemRNAs have short half-
lives, RNAi may be less effective while intrabodies can still function
effectively through direct binding to the proteins.
3.5. Efﬁcacy in animal studies and clinical trails
Geared toward a molecular therapy for human diseases, the
intrabody technology has been applied in animal studies and clinical
Table 1
Published scFvs against α-syn
Name Source
library
Epitope
(aa)
Binding to
α-syn
aggregates
Afﬁnity
(KD, M)
In vitro
effects
Intracellular
effects
F8[54] Phage 101–111/
27–37
? 10−8 Inhibit
aggregation
Unstable
expression
D10[25] Phage ⁎ Yes 10−6 ? Inhibit α-syn
aggregation
and rescue
impaired
adhesion
6E[55] Phage ⁎ Yes ? ? ?
3[57] Phage 71–85 Yes ? ? ?
14[57] Phage 106–120 Yes ? ? ?
15[57] Phage 117–131 Yes ? ? ?
D5[56] Phage ⁎ Yes ? Inhibit
aggregation
?
NAC3[26] Yeast 61–78 ? ? ? No signiﬁcant
protection
NAC24[26] Yeast 61–78 ? ? ? Unstable
expression
and no
signiﬁcant
protection
NAC32[26] Yeast 53–87 ? ? ? Inhibit α-syn
aggregation
and rescue
cytotoxicity
?: not reported.
⁎: The scFvs D10, 6E, and D5 recognize α-syn conformational epitopes, although the
amino acid sequences that constitute the epitopes are not identiﬁed.
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which induces in vitro transient phenotypic reversion of rodent
ﬁbroblasts transformed by ras, an oncogene, has been shown to invoke
sustained tumor regression in nude mice [37]. Moreover, an ER-
targeted intrabody against Tie-2, a receptor that is up-regulated in
capillaries during neovascularization processes produced in tumors,
has been shown to signiﬁcantly inhibit tumor growth in mouse
models [38]. More recently, the intrabody EM48 has been shown to
suppress neuropil aggregates in a mouse model of Huntington's
disease (HD) [39], thus indicating promising applications of intra-
bodies in neurodegenerative diseases. In the Phase I clinical trial using
an ER-targeted anti-erbB-2 intrabody, which had been previously
shown to prolong survival in human ovarian cancer xenograft models
[40], of 13 ovarian cancer patients with erbB-2 overexpression, 5
(38%) had stable disease and 8 (61%) had evidence of progressive
disease [41]. Except for showing that the intrabody approach is
feasible for human application with very limited side effects, this
clinical study indicates that compared to cellular and animal studies,
the intrabody technology, including gene delivery methods, needs to
be further developed to achieve a dramatic effect for the therapy of
human diseases.
4. Intrabody and PD
In light of the initial successful application of intrabodies in the
studies of AIDS and cancer, the intrabody technology has been
employed in the studies of neurodegenerative diseases with the
hopes of preventing abnormal protein aggregation. For instance, in
HD, the polyglutamine expansion in the huntingtin (htt) protein
causes htt aggregation, which is thought to be toxic to cells. It has
been shown that anti-htt intrabodies can inhibit mutant htt
aggregation and thus rescue cells from death [42,43] and the anti-
htt intrabody C4 shows in vivo efﬁcacy of protection in a Drosophila
model of HD [44]. Moreover, the intrabody EM48 has been shown to
suppress neuropil aggregates in a HD mouse model [39]. Another
example in the study of Alzheimer's disease is the use of intrabodies to
inhibit the generation of the toxic amyloid beta-peptide, by blocking
the beta-secretase cleavage site or by retaining the beta-amyloid
precursor protein in ER [45].
In the following sections, we will discuss the intrabody application
in PD. Although the intrabody technology can be used for studying all
PD-related proteins, here, we focus on α-syn and LRRK2, two proteins
that cause autosomal dominant PD, to demonstrate a proof of
principle of existing and future intrabody applications in PD.
4.1. α-Syn
α-Syn is a 140 amino acid protein that belongs to the synuclein
protein family, which also includes β-syn and γ-syn. Previous studies
using both optical methods and NMR have shown that α-syn exhibits
a random-coil structure (or natively unfolded structure) under
physiological conditions [46,47]. Mutations in α-syn cause a rare
form of PD. The fact that α-syn is the major component of LB, a
hallmark of PD, has put α-syn under intense study that eventually led
to the consensus that protein aggregation is one of the major
pathogenic mechanisms of PD. Although it is debatable whether LBs
are toxic or protective and which forms of aggregated α-syn such as
oligomers versus ﬁbrils mediate toxicity, it is clear that α-syn is a
natively unfolded protein that may acquire a gain of toxic function due
to self-aggregation [48–51]. Therefore, the development of anti-α-syn
intrabodies may be potentially useful in blocking α-syn aggregation
and therefore protect cells from toxic α-syn aggregates.
Natively unfolded proteins have been categorized as a novel
protein family — naturally unfolded (or intrinsically unstructured)
protein family. It is hypothesized that these natively unfolded proteins
often acquire ordered three-dimensional structures upon binding totheir partners, such as proteins and nucleic acids, and modify the
function of their partner molecules [52,53]. Based on the available
knowledge of natively unfolded proteins and previous studies on α-
syn, we propose a simpliﬁed paradigm of possible α-syn structure–
function relations as a working hypothesis for developing potential
protective intrabodies against PD (Fig. 3). In this schematic, α-syn
exists physiologically as a natively unfolded protein with the
potential of transforming into the following three ordered structures.
The available experimental evidence shows that the N-terminal
sequence of α-syn binds to acidic lipids and forms an α-helical
structure. One hypothesis is that α-syn functions on cellular
membranes once it acquires an ordered structure through binding
to the membranes. In addition, like other natively unfolded proteins,
α-syn may also bind to other multiple targets to play an important
role as a modiﬁer of various cellular pathways. While α-syn may
utilize its unfolded structure to adopt several possible ordered
structures to function, this possible biological beneﬁt comes with the
following potential downside: α-syn can form a stable β-sheet
structure by self-binding under certain conditions. The latter include
increased α-syn protein levels exceeding a threshold, genetic
mutations which cause potency for self-oligomerization, changes in
physiological conditions including oxidative stress, and post-transla-
tional modiﬁcations including dopamine-α-syn adducts. As a result,
when the protein quality control system of a cell becomes impaired,
the physiological balance that favors the formation of beneﬁcial α-
syn structures may abnormally favor α-syn self-aggregation. Such
self-aggregation may in turn underlie the formation of α-syn
aggregates, ﬁbrils and LBs.
Based on the above model, it is tempting to develop intrabodies
that can speciﬁcally block the self-binding of α-syn without affecting
the binding of α-syn to its physiological partner molecules (Fig. 3). In
the pioneer studies aimed at this goal, various scFvs against α-syn
have been generated and we have listed the majority of these in
Table 1. In the following, we will discuss several critical issues based
on the available studies of anti-α-syn scFvs and intrabodies to shed
light on future studies.
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As potential therapeutics for human diseases, intrabodies are often
generated by screening scFvs from human antibody libraries rather
than by cloning scFv gene segments from mouse hybridomas. Current
available anti-α-syn scFvs/intrabodies are selected from three phage
libraries and one yeast library (Table 1). ScFvs F8 [54], D10 [25], 6E
[55], and D5 [56] are selected from two synthetic libraries that containFig. 4. Anα-syn aggregation model in human neuroblastoma SH-SY5Y cells. (A) While the ce
protein aggregates, the α-syn-RFP transfected cells have perinuclear RFP-containing protein
the RFP-positive protein aggregates (red signals) are also α-syn positive by the immunostain
signals). The protein aggregates indicated by arrows are shown at higher magniﬁcation in
transfected cells are subjected for ﬂuorescent immunoblotting [82].α-Syn is detected by the
polyclonal anti-RFP antibody (Clontech Laboratories, Mountain View, CA) (red signals). The
thus indicating that themajority of overexpressedα-syn-RFP is full-length (∼45 KD) and furt
α-syn-RFP.synthesized variable regions of scFvs. On the other hand, scFvs NAC3,
NAC24, and NAC32 [26] are selected from a yeast library that is
composed of scFv gene segments from the mRNA pool of 58 human
adult spleens and lymph nodes. In addition, scFvs 3, 14 and 15 [57] are
from a phage library generated using the mRNAs from human
peripheral blood lymphocytes of a large (N100) pool of donors.
Thus, all the scFv libraries currently used for generating anti-α-synlls expressing RFP show homogenous distribution of RFP (red signals) without apparent
aggregates (red signals). Nuclei are shownwith DAPI labeling (blue signals). In addition,
ing with a mouse monoclonal anti-α-syn antibody (BD Biosciences, San Jose, CA) (blue
the insets. Scale bar, 5 μm. (B) The whole cell lysates extracted from RFP or α-syn-RFP
anti-α-syn antibody from BD Biosciences (green signals) and RFP is detected by a rabbit
merged image shows that the ∼45 kDa protein species is both α-syn and RFP positive,
her supporting that the perinuclear protein aggregates, shown in (A), contain full-length
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unimmunized individuals or are artiﬁcially synthesized. This suggests
that, despite the unique unfolded structure of α-syn, it is feasible to
screen anti-α-syn scFvs from current available large scFv libraries, no
matter what display platform a library adopts, or what screening
method a library employs. For example, phage libraries use a panning
protocol in which immobilized antigens are coated on a solid surface,
while yeast libraries use a ﬂow cytometry sorting protocol with free
antigens in solution (see [9] and [11] for detailed method descrip-
tions). Meanwhile, it also indicates that the initial screened scFvs from
these naïve antibody libraries may need to be engineered further to
improve their afﬁnities for the natively unfolded protein α-syn, or to
increase their thermal stabilities and antigen-binding speciﬁcities.
4.1.2. Antigens used for screening scFv libraries
α-Syn contains an N-terminal amphipathic region, a central
hydrophobic region known as the nonamyloid component (NAC, aa
61–95), and a C-terminal acidic tail. It has been reported that the NAC
region is the core sequence responsible for α-syn aggregation [58,59].
The N-terminal sequence has a propensity to bind with acidic lipids
whereas the C-terminal region appears to be involved in α-syn
aggregation [60,61]. Currently, the accurate molecular mechanisms of
α-syn self-binding and the formation of stable oligomers and ﬁbrils
are unclear. Therefore, there are no clear strategies for predicting
antigenic epitopes to produce anti-aggregation scFvs, but to explore
all of the possibilities. That is to useα-syn peptides,α-syn monomers,
and α-syn conformers (including α-syn oligomeric aggregates and
ﬁbrils) as antigens.With these antigens, it is hopeful that scFvs may be
generated against two kinds of potentially useful epitopes to inhibit
α-syn aggregation. One type of useful epitope is the linear α-syn
sequences that are the self-binding sites of two or more α-syn
monomers. Among scFvs that can bind to these sequences, it is
reasonable to select those that can block the self-binding sites and
thus inhibitα-syn oligomer formation. The identiﬁed sequences in the
NAC region (aa 68–76 or aa 71–82), which are required for α-syn
aggregation, are the most promising candidates in this aspect. Indeed,
scFv NAC32 is selected against a peptide containing the amino acids
53–87 of α-syn. When tested in mammalian cells as an intrabody, it
inhibited α-syn aggregation and reduced the cytotoxicity caused by
mutant α-syn. However, we cannot exclude other N-terminal or C-
terminal sequences as useful antigenic epitopes, sincewe do not know
how these two regions play their roles in α-syn aggregation. Another
type of useful epitope is the three-dimensional structures that are
important for aggregation formation. ScFvs against this kind of
epitope are also expected to block α-syn self-aggregation. For
example, scFv D10 recognizes a conformational epitope, inhibits the
formation of a high molecular weight α-syn species and rescues
impaired cell adhesion caused by overexpressed α-syn. For these
available anti-α-syn scFvs, a detailed description of the relationship
between the epitopes and their scFvs' capacity to inhibit α-syn
aggregation can be found in Table 1.
4.1.3. In vitro versus in situ characterization of scFvs
As we mentioned before, antigen-binding efﬁciencies of an scFv
between in vitro and intracellular conditions are often not consistent
due to the reducing environment of the cytosol. For example, both
scFv F8 and scFv D10 are selected against recombinant monomeric α-
syn from a human synthetic antibody library. ScFv F8 shows high
afﬁnity (KD=∼10−8 M) whereas scFv D10 has only low afﬁnity
(KD=∼10−6 M). However, when expressed intracellularly, scFv F8 is
very unstable whereas scFv D10 is quite stable. Surprisingly, scFv D10
is able to bind α-syn inside of mammalian cells and, further, to inhibit
the formation of a high molecular weight α-syn species. The
phenomenon of low-afﬁnity scFvs being functional intrabodies
might be addressed by two explanatory models of antigen–antibody
interaction, the “lock-and-key” and “induced ﬁt”models. In the “lock-and-key” model, the structures of the antigen-binding site and its
corresponding antigen are highly complementary. Therefore, only
minimum conformational changes are required when the antibody
binds to its antigen, yielding high afﬁnity. On the other hand, in the
“induced ﬁt”model, antigens, antibodies, or both, undergo conforma-
tional adjustments to facilitate antibody–antigen binding, thus
resulting in low afﬁnity [62]. It is likely that due to high intracellular
stability, some low-afﬁnity scFvs, such as scFv D10, can accumulate to
a certain amount in the cytosol and bind their antigens through an
“induced ﬁt” mechanism. Consistent with this hypothesis, other
studies also revealed that the stability is much more critical than the
in vitro afﬁnity for an scFv to be a functional intrabody [29]. Therefore,
while in vitro characterization is helpful for identifying scFv features,
it is critical to assess the performance of scFvs inside of mammalian
cells in order to generate functional intrabodies.
4.1.4. Intracellular characterization of intrabodies
From the above, it is apparent that intracellular stability and
“intracellular afﬁnity” are two critical aspects for evaluating the
potential of an scFv to be a functional intrabody. To evaluate
intracellular stability of scFvs, the pulse-chase method is a classic
way to determine protein half-lives. In general, an scFv with a half-life
of over 8 h would likely have a high intracellular steady state level in
order to be a functional intrabody. Meantime, it is also important that
a stable scFv can fold correctly in the cytosol to maintain its antigen-
binding efﬁciency in a reducing environment, i.e. “intracellular
afﬁnity”. Unfortunately, unlike in vitro afﬁnity assays, such as BIAcore,
a direct intracellular afﬁnity assay is currently not available. Therefore,
two intrabody binding assays have been established to test indirectly
for binding efﬁcacy between intrabodies and their antigens. One
strategy is to express scFvs tagged with organelle-targeting sequences
to gather scFvs at certain subcellular compartments, such as nuclei. If
an scFv binds to its intracellular antigen efﬁciently, it can convey its
antigen to the same organelle. As a result, both the scFv and its antigen
can be found to be enriched and colocalized in the same organelle by
immunocytochemistry. For example, co-overexpression of D10-NLS
(nuclear localization signal) and α-syn causes the enrichment and
colocalization of both proteins in the nuclei [25]. Of note, in scFv/
antigen co-transfection experiments, the degree of accumulation of
the scFv/antigen to a certain organelle varies from cell to cell. Thus, a
strict quantiﬁcation of the percentage and degree of the colocalization
would be helpful. For this, one can use subcellular fractionation with
Western blotting to assess the colocalization efﬁcacy, which can be
quantiﬁed with image quantiﬁcation softwares, such as Scion Image
and NIH Image. Another method to show the binding between
intrabodies and their antigens is the co-immunoprecipitation assay. In
this case, intrabodies and their antigens will be considered just as two
proteins overexpressed intracellularly. Co-immunoprecipitation is
used to evaluate whether or not intrabodies and their antigens bind
to each other inside of cells. For instance, the D10 intrabody shows
dose-dependent co-immunoprecipitation with α-syn [25]. In general,
when the above two strategies are applied, they may reveal whether
an scFv can bind its antigen effectively as an intrabody. For the future,
a direct and real-time binding assay is needed to assess the
“intracellular afﬁnity” of intrabodies in a more accurate way so that
an “intracellular KD” and a retention time can be given. Such elegant
intracellular quantiﬁcation assays will improve signiﬁcantly the
evaluation of intrabody characters.
4.1.5. Evaluation of anti-α-syn intrabody protective effects
Once efﬁcient anti-α-syn intrabodies have been identiﬁed, it is
critical to evaluate whether or not these intrabodies are protective.
Given that the physiological function of α-syn is still unclear, it is
necessary to test the protective effect of intrabodies on both of the
inhibition of α-syn aggregation and rescue from cytotoxicity caused
by α-syn, which model the pathogenic hallmarks of PD — Lewy body
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force microscope (AFM) imaging are widely used for in vitro study of
α-syn aggregation. Due to its aggregation-prone feature, α-syn
forms self-aggregates in common solvents, such as phosphate
buffers. By monitoring thioﬂavin T ﬂuorescence intensities, the
kinetics of α-syn aggregation can be established which allows one to
evaluate whether or not an intrabody inhibits α-syn aggregation
[49]. The AFM analysis, another in vitro tool, is often used to observe
α-syn aggregates directly, allowing identiﬁcation of various α-syn
aggregation stages, from small aggregates to ﬁlaments [49,52]. At the
cellular level, except for analyzing α-syn by immunoblotting [25],
ﬂuorescence-tagged α-syn may be used to model α-syn aggregation.
For instance, the α-syn-GFP fusion protein has been used to model
α-syn aggregation and its abnormal effects in yeast [63]. Similarly,
when a fusion protein of α-syn-red ﬂuorescent protein (RFP) is
overexpressed in human neuroblastoma SH-SY5Y cells, we observed
that the majority of overexpressed α-syn-RFP formed perinuclear
aggregates that are both α-syn and RFP positive (Fig. 4A).
Furthermore, ﬂuorescent immunoblotting shows that the majority
of overexpressed α-syn-RFP is full-length protein (Fig. 4B), thus
supporting α-syn-RFP overexpression as a model of α-syn aggrega-
tion in mammalian cells. Recently, cytotoxicity assays using ST14A
neuronal cells have been utilized to test the protective effect of
intrabodies against α-syn toxicity. Along this line, other established
α-syn cellular models, such as inducible α-syn overexpression in
PC12 cells [64] and overexpression of α-syn in primary cultured
dopaminergic neurons [65], may also be useful for the evaluation of
the key issue — the protective effects of anti-α-syn intrabodies
against neuronal death. Perhaps, the more challenging tests are
whether anti-α-syn intrabodies can perform protective functions in
vivo, especially in α-syn models in mice [66], Drosophila [67], Cae-
norhabditis elegans [68], etc.
4.1.6. Intrabody optimization
It is worth pointing out that after the initial identiﬁcation of
functional intrabodies that can bind to their antigens intracellularly,
certain optimization strategies can be applied to obtain robust
intracellular stability and “intracellular afﬁnity” (Fig. 2). For example,
the afﬁnity of scFvs derived from naïve antibody libraries often can be
further increased by random mutagenesis. Such mutagenesis can
create sub-libraries with ∼106 mutated scFvs. If sub-libraries are
screened against the same antigen, a set of scFvs with higher afﬁnities
can be obtained [69]. Recently, it has been shown that using yeast scFv
display, scFvs with high thermal stability can also be achieved by
mutagenesis [70]. With these further steps, intrabodies with opti-
mized intracellular stability and afﬁnity can be achieved eventually.
Such robust intrabodies should be ready for further in vivo applica-
tions, including clinical trials.
4.1.7. Summary
As discussed above, anti-α-syn scFvs/intrabodies have been
generated and tested for their potential protective effects against α-
syn malfunction. While these intrabodies show promising protective
effects, more extensive studies are needed in the following two areas.
First, robust intrabodies with optimized intracellular stability and
“intracellular afﬁnity” are needed in order to make intrabody as an
intracellular “magic bullet”. Currently, only two anti-α-syn scFvs, D10
and NAC32, have shown promising effects as intrabodies in inhibiting
α-syn aggregation and in rescuing α-syn toxicity. While both scFvs
show relative intracellular stability, they all have low afﬁnity.
Importantly, the production of anti-α-syn scFvs with high “intracel-
lular afﬁnity” is more likely to provide robust intrabodies as possible
therapeutics for PD. To achieve this goal, as we proposed, it would be
helpful to establish real-time analyses to evaluate intracellular
intrabody-α-syn dynamic interaction. That way, the intracellular
binding efﬁcacy of anti-α-syn intrabodies can be quantiﬁed andfurther used to generate high “intracellular afﬁnity” through muta-
genesis. Currently, since such “intracellular afﬁnity assays” are
unavailable, it may be important to generate the scFvs that have
both intracellular stability and in vitro high afﬁnity, with the
assumption that given the intracellular stability, the in vitro afﬁnity
may reﬂect a certain degree of “intracellular afﬁnity”. A strategy for
generating high afﬁnity scFvs with high intracellular stability is given
in Fig. 2. In addition, the speciﬁcity of anti-α-syn intrabodies for other
synuclein family proteins, such as β-syn and γ-syn, need to be tested.
For instance, the D10-NLS construct failed to convey β-syn to the
nucleus, thus indicating its relative speciﬁcity for α-syn inside cells.
This speciﬁcity issue also applies to other available anti-α-syn scFvs
listed in Table 1. The highly speciﬁc scFvs against α-syn, but not its
homologous proteins, aremore likely to avoid disturbing other normal
cellular functions. Second, the current studies of anti-α-syn intrabo-
dies are pioneer work for demonstrating proof of principle. To
generate valuable anti-α-syn intrabodies as therapeutics for PD, in-
depth studies are needed to answer the following questions: how
intrabodies inhibit α-syn aggregation; whether the binding of
intrabodies with α-syn can change α-syn degradation; whether or
not and how intrabodies can provide signiﬁcant protection against
dopaminergic neuron death; etc. Furthermore, to overcome the
intrinsic limitation of studies using cellular models, in vivo intrabody
effects on α-syn pathology could provide critical insight into the
potential of intrabody therapy for PD.
4.2. LRRK2
In the following, we will discuss brieﬂy a possible use of
intrabodies as potential therapeutics against cellular toxicity caused
by LRRK2. Recently, the importance of LRRK2 in PD has been
highlighted by the fact that LRRK2 is currently the most frequent
genetic cause of all PD cases.
LRRK2 is a large complex protein of 2,527 amino acids. It contains
several predicted functional domains: Roc (Ras in complex proteins),
COR domain (C-terminal of ROC), a leucine-rich repeat (LRR), a
protein kinase domain, a WD40 domain and an ankyrin domain. The
ROC domain has GTPase activity. Currently, the functions of some of
these domains, such as Roc, LRRs, Ankyrin, and WD40 domains, are
unknown.
Certain PD-linked LRRK2 mutations, such as G2019S and I2020T,
increase LRRK2 kinase activity, thus leading to neuronal toxicity
[71–73]. Accordingly, abolishing the kinase activity attenuates
cytotoxicity caused by mutant LRRK2, conﬁrming that the kinase
activity is likely a prerequisite for the toxic effects of mutant LRRK2
[74]. Therefore, blocking LRRK2 kinase activity by intrabodies could be
a potential therapeutic strategy against aberrant LRRK2 toxicity,
especially when using kinase domain-speciﬁc intrabodies, which do
not affect the function of other LRRK2 domains.
In addition, it has been shown that LRRK2 exists as a protein
complex, including homodimers. LRRK2 homodimerization is depen-
dent upon the interaction of the ROC GTPase domain and several other
domains, such as the LRR andWD40 domains [75]. Interestingly, it has
also been found that LRRK2 can form aggregates under certain
circumstances. For example, overexpression of mutant LRRK2 has led
to the formation of cytoplasmic aggregates or inclusions in various cell
types, suggesting that LRRK2 mutations promote protein misfolding
[74,76,77]. Therefore, intrabodies that can block LRRK2 misfolding
may be protective.
Except for self-binding, LRRK2 has been shown to interact with
other proteins, such as parkin [76] and Rab5b [78]. In addition,
LRRK2 may function on cellular membranes [71,79,80] or through
binding to microtubules [81]. With the function and toxicity of
LRRK2 being further elucidated, intrabodies may be useful for
blocking speciﬁc molecular events required for the gain of toxicity
of LRRK2.
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Clearly, intrabodies provide a useful tool to study protein function
intracellularly and, more importantly, have the potential to serve as
therapeutics for PD. Further development of intrabody technology,
such as new approaches to generating robust intracellular stability
and high “intracellular afﬁnity”, novel intrabody-effector fusion
proteins, organelle-speciﬁc intrabodies, and protein domain-speciﬁc
intrabodies, will maximize intrabody therapeutic efﬁcacy. In-depth
studies of the intrabody characters and their anti-PD effects and
mechanisms in various PDmodels, from in vitro to in vivo, will provide
solid evidence for exploring the potential of intrabody therapeutic
application. The development of gene deliverymethods, which are the
means of expressing intrabody in target cells, will increase the in vivo
therapeutic efﬁciency of intrabodies. In addition, since the studies on
the molecular mechanisms of PD pathology are advancing quickly,
newly identiﬁed “toxic” molecules will provide additional targets for
the intrabody therapy. Together, multi-ﬁeld advances in technology
and knowledge related to the intrabody therapy hold one of the
promises for the cure of PD.
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